NIH: 54M Americans Have Low Bone Density. Most Won’t Know Until a Fracture
Wyoming, United States – Aug 3, 2026 – An estimated 54 million Americans have osteoporosis or low bone mass, according to the National Institutes of Health, yet the condition is routinely called “silent” for a reason: most people get no warning until they break a bone. For the roughly 10 million Americans with full osteoporosis, that first fracture is often a hip fracture, and the NIH reports that up to 20% of hip fracture patients die within one year of the injury. OsteoIQ’s [Bone Turnover Marker Bundle and Genomics tests are now available direct-to-consumer, giving patients and the practitioners who work with them an actionable window into bone metabolism that doesn’t require a clinic visit or a referral.
Key Facts 54 million Americans have osteoporosis or low bone density, according to the National Institutes of Health Office of Dietary Supplements
$57 billion in annual U.S. costs are attributed to osteoporosis-related fractures, based on data from the Agency for Healthcare Research and Quality (AHRQ) Costs and Utilization Project
DXA scans, the current clinical standard for bone density measurement, typically detect bone loss only after significant structural change has already occurred, and most guidelines don’t recommend screening until age 65 for women without additional risk factors
OsteoIQ’s Bone Turnover Marker (BTM) Bundle measures biological indicators of bone resorption and bone formation in real time, giving users a picture of what bone metabolism is doing right now, not what bone structure looked like months ago
Testing intervals of 3, 6, or 12 months let users track whether interventions (diet, supplementation, weight-bearing exercise, medication) are actually moving their markers in the right direction
The Bone Health Intelligence app delivers personalized insights tied directly to a user’s own lab results and genomic profile, rather than population averages
Bone turnover markers have been used in clinical research for decades. The landmark OFELY study and subsequent NIH-funded trials demonstrated that elevated bone resorption markers, specifically serum CTX (C-terminal telopeptide) and urine NTX (N-terminal telopeptide), predict fracture risk independently of bone mineral density. That research has long been available to specialists. What hasn’t existed until recently is a direct path for a patient to run those same markers at home, see the results in context, and act on them without waiting six months for a follow-up appointment.
That gap is exactly where OsteoIQ sits. A DXA scan tells you where bone density stands today. It doesn’t tell you whether bone loss is accelerating, whether a new supplement protocol is working, or whether genetic variants affecting vitamin D metabolism or collagen production are putting you at elevated risk. OsteoIQ’s combination of biomarker testing and genomic analysis addresses each of those questions specifically. For practitioners, it also means objective data to bring into a consultation rather than relying solely on patient-reported symptoms or infrequent clinic imaging.
Consider a common situation: a woman in her mid-50s has a family history of osteoporosis and has started a calcium and vitamin D regimen, but her next scheduled DXA isn’t for another two years. She has no way to know whether her bone resorption rate is increasing, holding, or improving. A BTM test taken today gives her that information now, not at the point when structural damage is already visible on imaging. The genomic layer tells her whether she carries variants affecting how efficiently her body actually absorbs and uses what she’s supplementing. That’s a different category of information than a bone density score. For those exploring available osteoporosis lab testing panels, understanding what each marker measures is a useful first step before ordering.
One honest limit to set clearly: at-home bone turnover marker testing doesn’t replace clinical care, and it doesn’t diagnose osteoporosis. Results from OsteoIQ’s tests are meant to inform conversations with healthcare providers and personal health decisions, not to substitute for medical evaluation. For people who are already managing an osteoporosis diagnosis under physician supervision, these tools work alongside existing care, not instead of it. What they change is the frequency and specificity of the information available between appointments. Individuals with questions about how testing works can find answers through OsteoIQ’s frequently asked questions page.
About OsteoIQ
OsteoIQ provides at-home bone health testing through its Bone Turnover Marker Bundle and Genomics tests, paired with the Bone Health Intelligence app for personalized, data-driven insights. The platform is available direct-to-consumer globally, with testing intervals of 3, 6, or 12 months designed for ongoing monitoring rather than one-time screening. OsteoIQ’s approach combines real-time biomarker data with genetic analysis to give individuals and their healthcare providers a faster, more specific picture of bone health than traditional imaging alone provides.
Media Contact
Company Name: OsteoIQ
Contact Person: Kevin Ellis
Email: Send Email
City: Wyoming
Country: United States
Website: https://osteoiq.com/
